BOSTON, June 13, 2024 /PRNewswire/ -- LG Chem and AVEO Oncology, an LG Chem company, announced that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109 (NCT06332755; LG project code LR19155), LG Chem's first proprietary anti-cancer investigational drug candidate. LG Chem will be collaborating closely with AVEO Oncology, its wholly owned subsidiary, that specializes in oncology development and commercialization, to advance strategies for late-stage clinical development and regulatory approval.
More than 12 years ago, Aveo Oncology vaulted onto Nasdaq with an IPO pitch centered on its lead cancer drug, tivozanib. It took almost a decade, with an FDA rejection, multiple shareholder lawsuits and an SEC investigation along the way, but the biotech finally clinched an approval in the US last year.
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat Subjects with Refractory Cancer” (the “Application”). AVEO expects to receive a Notice of Allowance for this Application. This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2039.
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference. The panel titled “Building Combinations: What are the Novel Ideas?” will be held on Wednesday, September 28th, at 10:40 a.m. eastern time.
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September, including:
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the second quarter ended June 30, 2022.
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 4, 2022, to discuss the financial results and provide a business update.
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC